Wells Fargo raises Liquidia stock price target on improved outlook
Wells Fargo raised its price target for Liquidia Technologies (LQDA) to $40 from $33, citing improved demand outlook. The stock has gained 85% over the past year. LQDA reported Q3 revenue of $225.3M, beating estimates, but posted a GAAP EPS loss of $2.64 due to a settlement charge. Analysts from BTIG and Jefferies also raised their price targets, expressing confidence in the company's growth prospects.
How this was made
The 30-second read
Why it matters
The combination of a higher price target and earnings beat provides a fresh catalyst for short‑term traders.
Market read
New analyst targets and earnings beat create a short‑term buying opportunity for LQDA.
What to watch
Potential headwinds from uncertain demand for Yutrepia and ILD revenue erosion.
Background
Liquidia Technologies (NASDAQ:LQDA) recently settled a patent dispute and posted Q3 results that beat revenue estimates but showed a GAAP loss.
Ticker impact
Wells Fargo raised its price target on Liquidia Technologies to $40 and reported Q3 revenue beat, providing fresh analyst guidance and earnings data.
likely upward pressure as the market prices in the higher target and revenue beat
The new $40 target and better‑than‑expected revenue are fresh information that can move the stock in the near term.
Market effects
Positive for biotech and specialty pharma peers as the settlement clears a cloud over Liquidia.
U.S. biotech sector may see modest gains.
Limited to investors tracking niche inhaled‑therapy companies.
Counterpoint
The GAAP loss and settlement charge could weigh on the stock despite the target raise.
Key entities
- analystWells Fargo
Raised price target to $40, maintaining Equal Weight rating.
- analystBTIG
Raised price target to $87, maintaining Buy rating.
- analystJefferies
Raised price target to $62, maintaining Buy rating.
